RxDoctor Payments Data

Junaid Memon, MD

Internal Medicine · Scottsboro, ALNPI 1932143666

Payments from drug & device makers

$3,835in general payments, 2019–2025

Across 255 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$950
  • AbbVie$375
  • AstraZeneca$187
  • Novartis$164
  • Pfizer$144
  • plus $406 from 11 others

What the payments were for

  • Food & beverage$3,73597%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,835 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$396,709
Medicare patients
307
Services billed
11,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide197$215,127
EliquisApixaban191$195,500
MounjaroTirzepatide136$161,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$101,827
JanuviaSitagliptin Phosphate99$69,573
TrulicityDulaglutide48$53,090
JardianceEmpagliflozin44$49,693
Tresiba Flextouch U-100Insulin Degludec77$42,268
XareltoRivaroxaban47$38,660
RybelsusSemaglutide34$37,163
EntrestoSacubitril/Valsartan26$29,255
Tresiba Flextouch U-200Insulin Degludec43$28,263
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,856$27,880
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$25,334
FarxigaDapagliflozin Propanediol20$19,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,610$252,290231 claims
Lilly USA, LLCMounjaro, Trulicity$63$214,325184 claims
PfizerEliquis$144$195,500191 claims
GSKTrelegy Ellipta, Breo Ellipta$950$112,146117 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$187$62,06077 claims
Johnson & JohnsonXarelto$15$38,66047 claims
NovartisEntresto$164$29,25526 claims
Astellas Pharma US IncMyrbetriq$135$19,32931 claims
AbbVieLinzess$375$11,36111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Scottsboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →